Shares of Icon Plc (NASDAQ:ICLR) have earned a consensus recommendation of “Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $120.30.

ICLR has been the topic of a number of analyst reports. Zacks Investment Research downgraded Icon Plc from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. ValuEngine raised Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. SunTrust Banks, Inc. reissued a “buy” rating and set a $138.00 price target on shares of Icon Plc in a research report on Sunday, October 29th. Credit Suisse Group reissued an “outperform” rating and set a $120.00 price target (up previously from $105.00) on shares of Icon Plc in a research report on Monday, October 16th. Finally, Robert W. Baird reissued a “buy” rating and set a $123.00 price target on shares of Icon Plc in a research report on Thursday, October 12th.

WARNING: “Icon Plc (ICLR) Receives Average Rating of “Buy” from Analysts” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/20/icon-plc-iclr-receives-average-rating-of-buy-from-analysts.html.

Icon Plc (ICLR) opened at $117.25 on Monday. Icon Plc has a 12-month low of $73.76 and a 12-month high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The company has a market capitalization of $6,349.32, a P/E ratio of 22.50, a PEG ratio of 1.81 and a beta of 0.56.

Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.32 by $0.03. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The company had revenue of $440.30 million for the quarter, compared to the consensus estimate of $438.09 million. During the same quarter in the prior year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. sell-side analysts expect that Icon Plc will post 5.36 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of ICLR. Koch Industries Inc. boosted its holdings in shares of Icon Plc by 17,508.8% in the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock valued at $659,000 after purchasing an additional 662,357 shares in the last quarter. FMR LLC boosted its holdings in shares of Icon Plc by 38.4% in the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after purchasing an additional 635,950 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Icon Plc by 48.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after purchasing an additional 348,292 shares in the last quarter. Mckinley Capital Management LLC Delaware boosted its holdings in shares of Icon Plc by 2,674.8% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after purchasing an additional 326,320 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Icon Plc by 71.5% in the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after purchasing an additional 320,356 shares in the last quarter. 89.75% of the stock is currently owned by hedge funds and other institutional investors.

About Icon Plc

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.